What question did this study set out to answer?

This research aims to evaluate the efficacy of secukinumab in reducing symptoms of ankylosing spondylitis.

December 23, 2015Open Access

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Key Points

This research aims to evaluate the efficacy of secukinumab in reducing symptoms of ankylosing spondylitis.
Randomized trial involving dosing of secukinumab at 150 mg and 75 mg, with loading doses evaluated.
The efficacy was measured at week 16 for both dosing strategies.
ClinicalTrials.gov registrations: NCT01358175 and NCT01649375.
At week 16, 150 mg secukinumab significantly reduced ankylosing spondylitis symptoms.
75 mg secukinumab showed improvement but only when accompanied by a higher intravenous loading dose.

Abstract

Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenous loading dose. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and NCT01649375.).

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Key Points

Abstract

Cite This Study

Also Consider

Also Consider